What Hain Lifescience does

Hain Lifescience GmbH is a Germany-based manufacturer and distributor of molecular genetic in-vitro diagnostic (IVD) test systems for medical laboratories worldwide. Founded in 1986 in Nehren by brothers David and Tobias Hain as a mail order business for laboratory supplies, the company transitioned into proprietary IVD development and was rebranded as Hain Lifescience GmbH in 2001. Since August 2018 it has operated as a majority-owned subsidiary of Bruker within Bruker's Molecular Diagnostics division.

The company's offerings rest on three proprietary technology platforms: DNA·STRIP (reverse hybridization line probe assays), FluoroType® (real-time PCR with fluorescence-labeled probes), and LiquidArray® (next-generation multiplexing). The product portfolio spans infectious disease diagnostics (mycobacteria/TB with WHO endorsements, MRSA, gastrointestinal pathogens, sexually transmitted infections, respiratory viruses including SARS-CoV-2/Influenza/RSV), virology (HIV, HBV, HSV, CMV, EBV, VZV, BKV, Parvovirus B19), human genetics (thrombophilia, hemochromatosis, food intolerance, HLA-B27, metabolic disorders), and supporting instruments and reagents (FluoroCycler instruments, GenoXtract extraction devices, DNA/RNA extraction kits). Manufacturing is ISO 13485 certified and compliant with European IVD directive 98/79/EG.

Hain generates revenue through one-time sales of instruments (FluoroCycler 12/96/XT, GenoXtract, GT-Blot 48, TwinCubator, GTQ-Cycler 96) and recurring consumable sales (test kits, extraction kits, reagents) to medical laboratories. Distribution combines a German direct field sales team, wholly-owned subsidiaries in Spain, UK, France, South Africa, and Kenya, and an authorized distributor network covering more than 75 countries. The company employs over 100 people at its Nehren headquarters, with approximately half engaged in R&D, production, and quality functions.

Name

Hain Lifescience

Legal name

Hain Lifescience GmbH

Website

https://hain-lifescience.de

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

51–100 employees

Short description

Hain Lifescience GmbH is a Germany-based manufacturer of molecular genetic in-vitro diagnostic test systems — built on DNA·STRIP, FluoroType®, and LiquidArray® platforms — serving medical laboratories worldwide through direct sales, five subsidiaries, and distributors in 75+ countries, now operating as part of Bruker's Molecular Diagnostics division.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / In-Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics systems
• In-vitro diagnostic tests
• PCR-based detection kits
• Microbial identification assays
• DNA extraction instruments

Headquarters

HQ city

Nehren

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Molecular Diagnostic Test Systems: Sale of PCR-based and line probe assay test systems for detection of pathogens (bacteria, viruses, fungi), antibiotic resistances, and human genetic predispositions. Includes FluoroType® and GenoType® product lines.
2. Diagnostic Instruments: Sale and distribution of laboratory instruments including FluoroCycler® PCR cyclers, GenoXtract® extraction devices, GT-Blot 48, TwinCubator, and GTQ-Cycler 96.
3. Extraction Kits and Reagents: DNA/RNA extraction kits including FluoroLyse, GenoLyse®, GENO•CARD, GXT Extraction Kits for automated and manual nucleic acid isolation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Hain Lifescience GmbH develops, manufactures, and markets molecular diagnostic test systems based on PCR (polymerase chain reaction) and line probe assays for the detection of pathogens, antibiotic resistances, and human genetic predispositions. The portfolio spans instruments (e.g., FluoroCycler, GenoXtract), test kits, reagents, and consumables used across the full molecular diagnostics workflow from sample preparation to result analysis, serving medical and clinical laboratories worldwide.

Product overview

Hain Lifescience develops, manufactures, and distributes molecular genetic diagnostic test systems and instruments for medical laboratories worldwide. The product portfolio is built on three core technology platforms: DNA-STRIP (reverse hybridization), FluoroType (real-time PCR with fluorescence), and LiquidArray (next-generation multiplexing). The offerings span microbiology assays (mycobacteria including TB and NTM, MRSA, gastrointestinal pathogens, STIs), human genetics tests (thrombophilia, hemochromatosis, food intolerance, HLA-B27, metabolic disorders), virology assays (HIV, HBV, HSV, VZV, CMV, EBV, BKV, Parvovirus B19), and mycology testing. Supporting infrastructure includes automated and manual DNA extraction kits (GenoLyse, FluoroLyse, GENO-CARD, GXT kits, SpheroLyse) and instruments (FluoroCycler series, GenoXtract, GT-Blot, TwinCubator, GTQ-Cycler). Products are suitable for labs of all sizes from low to high throughput, with distribution in over 75 countries. The company is ISO 13485 certified and operates as a Bruker company since 2018.

Differentiator

Problem solved

Functional benefit

Brands

• LiquidArray: Next generation multiplexing technology providing comprehensive syndromic panel diagnostics with results at a glance in a familiar PCR format.
• FluoroType
• DNA STRIP
• FluoroCycler
• GenoType
• GenoQuick

Products and services

• FluoroType MTBDR VER 2.0

Quantifiable outcome

• MDR-TB detection within 2.5 hours with FluoroType MTBDR VER 2.0
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators7 records

Recent moves14 records

Expansion highlights5 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert system is the dominant rapid molecular diagnostics platform for TB (MTB/RIF, MTB/XDR) and infectious disease — directly competing with Hain's MTBDR and FluoroType MTBDR VER 2.0 tests in the same reference labs and global TB donor programs.
• ELITech Group: ELITech is a closely comparable mid-sized European IVD company offering sample preparation (e.g., easyMAG successor) and PCR-based infectious disease and human genetics kits — a near-direct peer in scale, distribution model, and target customer segments.

Broad incumbents

• bioMérieux: bioMérieux offers a broad microbiology and molecular diagnostics portfolio (BioFire FilmArray syndromic panels, VITEK MS, BACT/ALERT) directly overlapping Hain's microbiology, AMR, and syndromic testing franchises, with much greater hospital penetration and FDA-cleared products.
• QIAGEN: QIAGEN provides sample-preparation kits and PCR test systems (QIAstat-Dx, artus, NeuMoDx) that overlap Hain's extraction reagents, PCR assays, and emerging syndromic multiplexing — particularly in human genetics and infectious disease testing.
• Hologic: Hologic's Panther/Panther Fusion system (Aptima assays for STIs, respiratory viruses, virology) directly competes with Hain's STI and virology panels; Hologic's acquisition of Mobidiag also added GI syndromic panels overlapping LiquidArray Gastrointestinal.
• Abbott Molecular: Abbott's m2000 and Alinity m molecular diagnostics systems, together with the RealTime MTB/RIF assay, compete with Hain in TB diagnostics and broader virology/AMR testing across large hospital and reference lab networks.
• Roche Diagnostics: Roche's cobas 6800/8800 and cobas Liat systems dominate high-throughput molecular diagnostics, competing with Hain across virology (HIV viral load, HBV, CMV), women's health, and increasingly syndromic testing.
• BD (Becton Dickinson): BD's BD MAX system with open and on-board assays (including TB, STI, enteric panels) competes with Hain's mid-throughput molecular diagnostics in hospital and reference labs, particularly in the US market.

Emerging players

• R-Biopharm: R-Biopharm is a German mid-sized IVD manufacturer offering molecular and immunological tests for infectious diseases (including TB, GI, and STIs) — overlapping Hain's microbiology menu while being a smaller emerging competitor in the same European market.
• Mobidiag (Hologic): Acquired by Hologic, Mobidiag's Amplidiag and Novodiag platforms target GI and AMR molecular diagnostics — directly overlapping Hain's LiquidArray Gastrointestinal and AMR franchises in European hospital markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hain-lifescience-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hain Lifescience